FDA lifts clinical hold of MaaT Pharma's lead microbiome therapeutic trial

24 April 2023

Shares of French biotech Maat Pharma (Euronext Paris: MAAT) edged up more thatn 2% to 9.70 euros this morning, after it revealed that the US Food and Drug Administration (FDA) has lifted the clinical hold and cleared it Phase III Investigational New Drug (IND) application for lead microbiome ecosystem therapy (MET) candidate, MaaT013, in patients with acute Graft-versus-Host Disease (aGvHD).

Maat noted that is a significant milestone for the microbiome space, as well as for the company, as this is the first time the FDA has authorized the Phase III clinical evaluation of a microbiota-based live biotherapeutic based on a pooling (process of combining multiple donor samples) technology, in the USA.

In parallel to the resolution of the clinical hold with the FDA, the development of MaaT013 has significantly progressed in the  ongoing international multicenter open-label, single arm, pivotal Phase III trial (ARES) launched in March 2022 in Europe, along with the ongoing accumulation of encouraging data from the Early Access Program.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber



Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight

More Features in Biotechnology